COL6A3 (Collagen Type VI Alpha 3 Chain)

Bioinformatics analysis further suggested enrichment of crotonylated proteins in the ribosome pathway within psoriatic lesions. Overall, this study offers preliminary evidence of altered lysine crotonylation in psoriatic skin and suggests its potential involvement in psoriasis pathogenesis.

Additionally, dysregulation of CDK activity through CCND2, CCND3, and CCNB2 overexpression indicated accelerated cell cycle progression and evasion of DNA damage checkpoints. Together, this integrative analysis highlights ECM remodeling, cytoskeletal dynamics, and lipid metabolism as major contributors to cisplatin resistance and identifies potential therapeutic markers for TNBC.

Taken together, these results strongly suggest that pharmacological blockade of endotrophin cleavage, by using nigericin, effectively decreases endotrophin levels and improves endotrophin-mediated fibroinflammation and insulin resistance in obesity. Furthermore, this new therapeutic strategy could be applied to various metabolic diseases and solid tumors where endotrophin levels are pathologically elevated.

This study underscores the integration of AI, multi-omics, and in vitro studies for the discovery of candidate biomarkers and mechanistic insights into pathway modulation by Embelin in colorectal cancer. The research successfully identified and validated the role of COL6A3 as a potential biomarker and putative target modulated by Embelin in colon cancer.

In metabolic dysfunction-associated HCC induced by diethylnitrosamine (DEN) plus high-fat diet (HFD), dual knockout of Col6a3 and Cd44 in mice markedly reduced tumor burden, restored sorafenib sensitivity, and attenuated EMT, fibrosis, and steatotic-fibrotic niche formation. These findings establish the ETP-CD44-STAT3 axis as a driver of tumor-stroma crosstalk linking fibro-inflammation to malignancy, highlighting it as a therapeutic target in obesity-associated liver cancer.

RRSM is a potential prognostic predictor for STS and lays a foundation for early intervention of high-risk STS patients. The expression of genes FZD7, ITPKA, and PRKAG1 may guide STS treatment decisions.

Our findings underscore the significant role of rare, high-penetrance genetic variants in FLC susceptibility, particularly in mucin glycosylation and DNA repair genes. These findings offer promising targets for early detection and personalized therapies.

Groups 1 and 3 exhibited linear increases with MA, whereas group 2 showed nonlinear increases. In conclusion, the identification of plasma proteomic biomarkers and their undulating changes in metabolic aging provides a critical foundation for developing clinical markers and precision interventions to prevent accelerated metabolic aging.

This fusion drives tumorigenesis and forms the basis for imatinib treatment, which acts by blocking platelet-derived growth factor receptor-beta kinase activity...In this editorial commentary, we briefly highlight the ever-growing genomic landscape of DFSP, report rare fusions and their biological implications, and examine the role of expanded molecular diagnostics in refining diagnosis, guiding therapy, and informing prognosis. Incorporating comprehensive fusion analysis into routine workup may be critical for accurate classification, especially in unusual presentations where reliance on morphology alone risks misdiagnosis.

Our study defines COL6A3+ GAFs as a key feature of GBM, driving vascular dysfunction and hypoxi, and suggests COL6A3 as a promising therapeutic target for disrupting fibrosis-angiogenesis crosstalk in GBM.

Finally, we speculate on the potential of serum ETP as a prognostic biomarker in both carcinomas and sarcomas. In summary, COL6A3 and ETP are powerful drivers of tumor growth that have potential as noninvasive diagnostic and prognostic tools for the clinical management of cancer.

Our findings highlight the critical role of COL6A3+ TAFs in regulating MDM function and spatial distribution, as well as their contribution to fibrotic tumor vasculature formation. Additionally, we propose targeting COL6A3+ TAFs with cilengitide as a potential therapeutic strategy.